AIM ImmunoTech Inc (AIM) has released an update to notify the public and investors about a regulation fd disclosure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM ImmunoTech has announced positive preliminary results from a Phase 2 study on Ampligen’s effectiveness in treating post-COVID conditions, generating buzz among investors. A video interview with Dr. Chris McAleer, AIM’s Scientific Officer, discussing these findings is available for further insights on the Virtual Investor platform, signaling a potential breakthrough that could impact the company’s stock value. This development is not officially filed but is provided to the public for informational purposes.
For further insights into AIM stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.